These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23141911)

  • 1. Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolites.
    Tichenor MS; Keith JM; Jones WM; Pierce JM; Merit J; Hawryluk N; Seierstad M; Palmer JA; Webb M; Karbarz MJ; Wilson SJ; Wennerholm ML; Woestenborghs F; Beerens D; Luo L; Brown SM; Boeck MD; Chaplan SR; Breitenbucher JG
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7357-62. PubMed ID: 23141911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors.
    Keith JM; Tichenor MS; Apodaca RL; Xiao W; Jones WM; Seierstad M; Pierce JM; Palmer JA; Webb M; Karbarz MJ; Scott BP; Wilson SJ; Wennerholm ML; Rizzolio M; Rynberg R; Chaplan SR; Breitenbucher JG
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3109-3114. PubMed ID: 27189675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase.
    Keith JM; Jones W; Pierce JM; Seierstad M; Palmer JA; Webb M; Karbarz M; Scott BP; Wilson SJ; Luo L; Wennerholm M; Chang L; Rizzolio M; Rynberg R; Chaplan S; Guy Breitenbucher J
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127463. PubMed ID: 32784090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
    Gustin DJ; Ma Z; Min X; Li Y; Hedberg C; Guimaraes C; Porter AC; Lindstrom M; Lester-Zeiner D; Xu G; Carlson TJ; Xiao S; Meleza C; Connors R; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2492-6. PubMed ID: 21392988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
    Roughley SD; Browne H; Macias AT; Benwell K; Brooks T; D'Alessandro J; Daniels Z; Dugdale S; Francis G; Gibbons B; Hart T; Haymes T; Kennett G; Lightowler S; Matassova N; Mansell H; Merrett A; Misra A; Padfield A; Parsons R; Pratt R; Robertson A; Simmonite H; Tan K; Walls SB; Wong M
    Bioorg Med Chem Lett; 2012 Jan; 22(2):901-6. PubMed ID: 22209458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure based design of novel irreversible FAAH inhibitors.
    Wang JL; Bowen SJ; Schweitzer BA; Madsen HM; McDonald J; Pelc MJ; Tenbrink RE; Beidler D; Thorarensen A
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5970-4. PubMed ID: 19765986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
    Vincent F; Nguyen MT; Emerling DE; Kelly MG; Duncton MA
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6793-6. PubMed ID: 19850474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase.
    Keith JM; Jones WM; Pierce JM; Seierstad M; Palmer JA; Webb M; Karbarz MJ; Scott BP; Wilson SJ; Luo L; Wennerholm ML; Chang L; Brown SM; Rizzolio M; Rynberg R; Chaplan SR; Breitenbucher JG
    Bioorg Med Chem Lett; 2014 Feb; 24(3):737-41. PubMed ID: 24433863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
    Minkkilä A; Saario SM; Käsnänen H; Leppänen J; Poso A; Nevalainen T
    J Med Chem; 2008 Nov; 51(22):7057-60. PubMed ID: 18983140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
    Johnson DS; Ahn K; Kesten S; Lazerwith SE; Song Y; Morris M; Fay L; Gregory T; Stiff C; Dunbar JB; Liimatta M; Beidler D; Smith S; Nomanbhoy TK; Cravatt BF
    Bioorg Med Chem Lett; 2009 May; 19(10):2865-9. PubMed ID: 19386497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold.
    Morera L; Labar G; Ortar G; Lambert DM
    Bioorg Med Chem; 2012 Nov; 20(21):6260-75. PubMed ID: 23036333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
    Gattinoni S; Simone CD; Dallavalle S; Fezza F; Nannei R; Battista N; Minetti P; Quattrociocchi G; Caprioli A; Borsini F; Cabri W; Penco S; Merlini L; Maccarrone M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4406-11. PubMed ID: 20591666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
    Seierstad M; Breitenbucher JG
    J Med Chem; 2008 Dec; 51(23):7327-43. PubMed ID: 18983142
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.
    Meyers MJ; Long SA; Pelc MJ; Wang JL; Bowen SJ; Schweitzer BA; Wilcox MV; McDonald J; Smith SE; Foltin S; Rumsey J; Yang YS; Walker MC; Kamtekar S; Beidler D; Thorarensen A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6545-53. PubMed ID: 21924613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
    Keith JM; Apodaca R; Xiao W; Seierstad M; Pattabiraman K; Wu J; Webb M; Karbarz MJ; Brown S; Wilson S; Scott B; Tham CS; Luo L; Palmer J; Wennerholm M; Chaplan S; Breitenbucher JG
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4838-43. PubMed ID: 18693015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
    Morera E; De Petrocellis L; Morera L; Moriello AS; Ligresti A; Nalli M; Woodward DF; Di Marzo V; Ortar G
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6806-9. PubMed ID: 19875281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
    Kodani SD; Bhakta S; Hwang SH; Pakhomova S; Newcomer ME; Morisseau C; Hammock BD
    Bioorg Med Chem Lett; 2018 Feb; 28(4):762-768. PubMed ID: 29366648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel propanamides as fatty acid amide hydrolase inhibitors.
    Deplano A; Morgillo CM; Demurtas M; Björklund E; Cipriano M; Svensson M; Hashemian S; Smaldone G; Pedone E; Luque FJ; Cabiddu MG; Novellino E; Fowler CJ; Catalanotti B; Onnis V
    Eur J Med Chem; 2017 Aug; 136():523-542. PubMed ID: 28535469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors.
    Sunduru N; Svensson M; Cipriano M; Marwaha S; Andersson CD; Svensson R; Fowler CJ; Elofsson M
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):513-521. PubMed ID: 28114819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.
    Kono M; Matsumoto T; Kawamura T; Nishimura A; Kiyota Y; Oki H; Miyazaki J; Igaki S; Behnke CA; Shimojo M; Kori M
    Bioorg Med Chem; 2013 Jan; 21(1):28-41. PubMed ID: 23218778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.